Caribou Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Caribou Biosciences's estimated annual revenue is currently $8M per year.
- Caribou Biosciences's estimated revenue per employee is $49,814
- Caribou Biosciences's total funding is $167.5M.
- Caribou Biosciences's current valuation is $698.8M. (January 2022)
Employee Data
- Caribou Biosciences has 161 Employees.
- Caribou Biosciences grew their employee count by 24% last year.
Caribou Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief People Officer | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Chief People Officer | Reveal Email/Phone |
4 | VP Finance and Controller | Reveal Email/Phone |
5 | VP Human Resources | Reveal Email/Phone |
6 | SVP Translational Sciences and Therapeutics Discovery | Reveal Email/Phone |
7 | VP Program Management - Therapeutics Product Development | Reveal Email/Phone |
8 | VP Medical Affairs and Project Leadership | Reveal Email/Phone |
9 | VP Clinical Development | Reveal Email/Phone |
10 | VP Platform Research | Reveal Email/Phone |
Caribou Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Caribou Biosciences?
Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. Interested in joining our team Please contact us at jobs AT cariboubio DOT com.
keywords:Biotechnology, Synthetic Biology, Agriculture
$167.5M
Total Funding
161
Number of Employees
$8M
Revenue (est)
24%
Employee Growth %
$698.8M
Valuation
N/A
Accelerator
Caribou Biosciences News
Caribou Biosciences, Inc. Cellecta, Inc. CRISPR Therapeutics AG; Editas Medicine, Inc. GeneCopoeia, Inc. GeneScript Biotech Corporation; Horizon...
Equities analysts anticipate that Caribou Biosciences will post -1.53 EPS for the current year. CRBU has been the subject of several research...
About Caribou Biosciences, Inc. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing...
From Biopharma Dive Caribou’s large IPO is suggestive of the progress scientists have made developing CRISPR as a gene editing tool over the decade since the publication of landmark research from last year’s Nobel Prize winners Jennifer Doudna and Emmanuelle Charpentier. At $304 million, Carib ...
"CRISPR pioneer Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform. Caribou co-founder and CRI ...
Other Companies in Berkeley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $57.2M | 161 | 4% | N/A |
#2 | $15M | 161 | 10% | N/A |
#3 | $1.7M | 164 | 9% | N/A |
#4 | $3.5M | 165 | 3% | N/A |
#5 | $25.6M | 166 | 32% | N/A |